Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Celalettin
C
Ustun
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Nicole
N
Randall
Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Eitan
E
Podgaetz
Department of Pathology and Laboratory Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Khalid
K
Amin
Department of Pulmonary, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
H Erhan
HE
Dincer
D000368:Aged; D000069439:Dasatinib; D004417:Dyspnea / Q000139:chemically induced* / Q000000981:diagnostic imaging; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010996:Pleural Effusion / Q000139:chemically induced / Q000000981:diagnostic imaging; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; D000069439:Dasatinib
Drug induced Lung Disease; Pleural Disease